TB-500 (Thymosin Beta-4) Raw Material

Overview

TB-500 is the synthetic peptide equivalent of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid protein present in virtually all human and animal cells. Thymosin Beta-4 was first isolated from bovine thymus tissue and has since been identified as a primary regulator of actin polymerization — a process fundamental to cell migration, wound repair, and tissue regeneration. As a synthetic equivalent, TB-500 replicates the biological activity of endogenous Tβ4 and is used in research models across cardiovascular, musculoskeletal, dermal, ocular, and neurological tissue-repair applications. Its systemic distribution and multi-tissue activity profile distinguish it from peptides with more targeted mechanisms of action.

Technical Specifications

Key Research Findings

The cardiovascular applications of Thymosin Beta-4 are among the most clinically developed in the literature. Crockford (2010) reviewed evidence from multiple preclinical models showing that Tβ4 promotes cardiac progenitor cell migration, reduces myocardial inflammation following ischemia, and supports angiogenesis through upregulation of HIF-1α and VEGF — suggesting potential utility in ischemic heart disease recovery programs [1]. These findings have underpinned ongoing interest from cardiovascular research groups and formulators working on cardioprotective peptide applications, where the compound’s tolerability profile in animal models is a key consideration in candidate selection.

In musculoskeletal and wound-healing research, Goldstein et al. (2012) reviewed Tβ4’s role in actin sequestration and cell migration across skin, muscle, corneal, and tendon models, noting consistent promotion of tissue repair with anti-inflammatory activity mediated through down-regulation of NF-κB [2]. This dual mechanism — simultaneously accelerating repair and dampening inflammation — is cited as a key reason TB-500 is used in multi-peptide research stacks alongside anti-inflammatory compounds such as BPC-157 and KPV, where complementary pathways are explored for synergistic effects in preclinical settings.

Why Purity Matters

At 43 amino acids and approximately 4,963 g/mol, TB-500 (Thymosin Beta-4) is a larger synthetic peptide where synthesis-related impurities — including truncation sequences, oxidized methionine variants, and incomplete N-terminal acetylation — are more likely than in shorter peptides. These structural variants can alter actin-binding affinity or reduce anti-inflammatory activity in a dose-dependent manner, producing inconsistent results across experimental replicates. For peptide manufacturers incorporating TB-500 into formulation batches and requiring supplier documentation for quality audits, HPLC-verified purity at ≥99.9% with MS identity confirmation ensures batch-to-batch consistency and documentation traceability.

References:
[1] Crockford D. Development of thymosin beta4 for treatment of patients with ischemic heart disease. Ann N Y Acad Sci. 2010;1194:184–93. PMID: 20536466
[2] Goldstein AL, et al. Thymosin β4: a multifunctional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37–51. PMID: 22107186

Quality & Documentation

Each batch of TB-500 raw material is individually tested before shipment. Included with every order:

• HPLC purity verification (≥99.9%)
• Mass spectrometry (MS) identity confirmation
• Batch number for full traceability

COA available upon request before order commitment.

FAQ

Q: Is TB-500 available in liquid formulation?
Yes, liquid formulation is available on request. Please specify your preferred concentration and solvent when inquiring.

Q: How should TB-500 raw material be stored?
Store at −20°C, sealed, away from light and moisture. Shelf life is 24 months under proper conditions.

Q: Is TB-500 the same as Thymosin Beta-4?
TB-500 is the common trade name for synthetic Thymosin Beta-4 (Tβ4), the same 43-amino acid peptide sequence (CAS 77591-33-4). The two names refer to the same compound and are used interchangeably in research literature and supplier documentation.